Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), ...

Novartis’ Cosentyx (secukinumab) has failed to show any benefit in the Phase III study in adults with newly diagnosed or ...

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial ...

Novartis is falling farther behind AbbVie, which expanded its JAK inhibitor Rinvoq into giant cell arteritis in April.

Novartis (NVS) stock slips as the company's anti-inflammatory agent Cosentyx fails primary goal in a Phase 3 trial for giant ...

NVS' Cosentyx fails to meet its primary goal in a phase III study for giant cell arteritis, despite favorable safety data.

Novartis' blockbuster immunology drug Cosentyx has disappointed in a phase 3 trial involving patients with giant cell ...

Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).

A late-stage trial testing Novartis’ Cosentyx in individuals with giant cell arteritis failed to meet its primary endpoint. The phase 3 study tested Cosentyx alongside a 26-week steroid taper and ...

Novartis fails in late-stage trial for Cosentyx in giant cell arteritis Jul. 03, 2025 7:06 AM ET Novartis AG (NVS) Stock, NVSEF Stock By: Dulan Lokuwithana, SA News Editor Play (1min) ...

The pharmaceutical company said Thursday the drug did not meet its primary endpoint of sustained remission after 52 weeks of use in a phase three trial. Novartis said it will complete a full ...

Novartis announced top-line results from the phase III GCAptAIN study evaluating Cosentyx (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx ...